PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)-Reference-Cited by-同舟云学术

PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC)

Published:2024-01 Issue: Volume:187 Page:107438
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Cavazzoni A.^ORCID,Digiacomo G.,Volta F.,Alfieri R.,Giovannetti E.,Gnetti L.,Bellini L.,Galetti M.,Fumarola C.,Xu G.,Bonelli M.,La Monica S.,Verzè M.,Leonetti A.,Eltayeb K.,D'Agnelli S.,Moron Dalla Tor L.,Minari R.,Petronini P.G.,Tiseo M.

Funder

Boehringer Ingelheim

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference61 articles.

1. First-Line Immunotherapy for Non-Small-Cell Lung Cancer;Reck;J. Clin. Oncol.,2022

2. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer;Hellmann;N. Engl. J. Med.,2019

3. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment;Hudson;Front. Immunol.,2020

4. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity;Gato-Canas;Cell Rep.,2017

5. The intracellular signalosome of PD-L1 in cancer cells;Escors;Signal Transduct. Target. Ther.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Antibody Therapies in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents;Frontiers in Pharmacology;2024-08-05

3. Bioinformatics-based discovery of biomarkers and immunoinflammatory targets in children with cerebral palsy: An observational study;Medicine;2024-04-19

4. Preclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy;International Immunopharmacology;2024-03

5. Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic Agents;2024-01-25